BIOLINERX LTD-SPONS ADR (BLRX)
US09071M2052 - ADR
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as...
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
BLRX stock results show that BioLine Rx beat on revenue for the second quarter of 2024.
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the second quarter of 2024.T...
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning!
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the first quarter of 2024.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the first quarter of 2024.Bi...
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Steady growth in APHEXDA® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at...
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Announces $6 Million Registered Direct Offering
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the fourth quarter of 2023.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the fourth quarter of 2023.B...
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
When you want to light your afterburners, these ideas will do the trick.
BioLineRx files for a $250M mixed securities shelf (NASDAQ:BLRX)
BioLineRx (BLRX) has filed a prospectus for a mixed shelf offering to raise up to $250M, indicating potential growth in their financial capital.
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
biolinerx GAAP EPS of -$0.01 (NASDAQ:BLRX)
BiolineRx, a biopharmaceutical company, reports Q3 2023 financial results, with a GAAP EPS of -$0.01.
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
- Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent...
3 Tech Stocks That Wall Street Loves More Than Nvidia
Purchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market.
3 Top Penny Stocks to Make You a Millionaire in 5 Years
Penny stocks can make you a millionaire with patience and luck especially when you follow secular trends overall.
BioLineRx announces closing of exclusive license agreement with GloriaBio (NASDAQ:BLRX)
BioLineRx announced a license agreement with GloriaBio for the development of motixafortide in Asia, including potential milestones and equity investment.